News
Reported Earlier, Roche's Genentech Announced Data From Stage 1 Of The National Institutes Of Health (NIH)-Sponsored Pivotal Phase III Outmatch Study Evaluating The Efficacy And Safety Ofxolair®
26 Feb 24
News
Roche Collaborates With PathAI To Expand Digital Pathology Capabilities For Companion Diagnostics
13 Feb 24
News
Repare Therapeutics To Regain Global Development, Commercialization Rights To Camonsertib (RP-3500), As Roche Notified That, Effective May 7, 2024, It Is Terminating License And Collaboration Agreement
12 Feb 24
News
Roche's Genentech Announces New 72-Week Data From BALATON And COMINO, Evaluating Vabysmo® In Macular Edema Due To Branch And Central Retinal Vein Occlusion
1 Feb 24
News